Clinical trial
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed…
NCT00060346 · Eastern Cooperative Oncology Group, Other · Terminated
Key facts
| NCT number | NCT00060346 |
|---|---|
| Title | Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia |
| Official title | Phase II Pilot Study Of Rituximab Plus CHOP In Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | rituximab, cyclophosphamide, Doxorubicin, Prednisone, Vincristine |
| Enrollment | 16 |
| Start date | Oct 5, 2004 |
| Primary completion | Dec 1, 2011 |
| Completion | Aug 1, 2012 |
| First posted | May 7, 2003 |
| Last update posted | Jun 29, 2023 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: